John G Ullman & Associates Inc Abbott Laboratories Transaction History

John G Ullman & Associates Inc

  • $649 Million
  • Q3 2024

A detailed history of John G Ullman & Associates Inc transactions in Abbott Laboratories stock. As of the latest transaction made, John G Ullman & Associates Inc holds 30,617 shares of ABT stock, worth $3.61 Million. This represents 0.54% of its overall portfolio holdings.

Number of Shares
30,617
Previous 30,527 0.29%
Holding current value
$3.61 Million
Previous $3.17 Million 10.03%
% of portfolio
0.54%
Previous 0.5%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024
BUY
$100.07 - $118.13 $9,006 - $10,631
90 Added 0.29%
30,617 $3.49 Million
Q2 2024

Aug 08, 2024
SELL
$100.73 - $112.44 $18,332 - $20,464
-182 Reduced 0.59%
30,527 $3.17 Million
Q1 2024

May 06, 2024
SELL
$109.52 - $120.96 $29,022 - $32,054
-265 Reduced 0.86%
30,709 $3.49 Million
Q4 2023

Jan 31, 2024
BUY
$90.19 - $110.4 $11,724 - $14,352
130 Added 0.42%
30,974 $3.41 Million
Q2 2023

Aug 21, 2023
SELL
$100.78 - $112.29 $10,078 - $11,229
-100 Reduced 0.32%
30,844 $3.36 Million
Q1 2023

May 05, 2023
SELL
$96.86 - $114.01 $12,107 - $14,251
-125 Reduced 0.4%
30,944 $3.13 Million
Q4 2022

Feb 08, 2023
SELL
$95.06 - $111.52 $6,178 - $7,248
-65 Reduced 0.21%
31,069 $3.41 Million
Q3 2022

Oct 19, 2022
SELL
$96.76 - $112.03 $12,578 - $14,563
-130 Reduced 0.42%
31,134 $3.01 Million
Q1 2022

Apr 29, 2022
SELL
$114.02 - $139.04 $18,243 - $22,246
-160 Reduced 0.51%
31,264 $3.7 Million
Q4 2021

Jan 26, 2022
SELL
$115.53 - $141.46 $24,723 - $30,272
-214 Reduced 0.68%
31,424 $4.42 Million
Q3 2021

Nov 02, 2021
SELL
$116.66 - $129.06 $34,998 - $38,718
-300 Reduced 0.94%
31,638 $3.74 Million
Q2 2021

Jul 23, 2021
SELL
$105.79 - $124.53 $31,737 - $37,359
-300 Reduced 0.93%
31,938 $3.7 Million
Q1 2021

Apr 22, 2021
SELL
$108.84 - $128.23 $4.04 Million - $4.76 Million
-37,100 Reduced 53.51%
32,238 $3.86 Million
Q4 2020

Feb 05, 2021
SELL
$105.0 - $114.42 $12,600 - $13,730
-120 Reduced 0.17%
69,338 $7.59 Million
Q3 2020

Nov 06, 2020
SELL
$91.64 - $111.29 $1.5 Million - $1.83 Million
-16,421 Reduced 19.12%
69,458 $7.56 Million
Q2 2020

Jul 29, 2020
SELL
$76.57 - $98.0 $2,450 - $3,136
-32 Reduced 0.04%
85,879 $7.85 Million
Q1 2020

Apr 14, 2020
SELL
$62.82 - $91.86 $157,426 - $230,201
-2,506 Reduced 2.83%
85,911 $6.78 Million
Q4 2019

Jan 29, 2020
SELL
$78.51 - $87.4 $64,456 - $71,755
-821 Reduced 0.92%
88,417 $7.68 Million
Q3 2019

Oct 21, 2019
SELL
$81.84 - $88.74 $61,052 - $66,200
-746 Reduced 0.83%
89,238 $7.47 Million
Q2 2019

Aug 02, 2019
SELL
$72.88 - $85.0 $2.91 Million - $3.39 Million
-39,938 Reduced 30.74%
89,984 $7.57 Million
Q1 2019

Apr 30, 2019
SELL
$66.22 - $80.06 $3.02 Million - $3.65 Million
-45,595 Reduced 25.98%
129,922 $10.4 Million
Q4 2018

Jan 29, 2019
SELL
$65.56 - $74.27 $242,375 - $274,576
-3,697 Reduced 2.06%
175,517 $12.7 Million
Q3 2018

Nov 02, 2018
SELL
$60.81 - $73.36 $2.85 Million - $3.44 Million
-46,916 Reduced 20.75%
179,214 $13.1 Million
Q2 2018

Jul 23, 2018
SELL
$57.57 - $63.54 $180,194 - $198,880
-3,130 Reduced 1.37%
226,130 $13.8 Million
Q1 2018

Apr 19, 2018
SELL
$56.27 - $63.62 $2.18 Million - $2.46 Million
-38,732 Reduced 14.45%
229,260 $13.7 Million
Q4 2017

Jan 31, 2018
SELL
$53.68 - $57.47 $216,867 - $232,178
-4,040 Reduced 1.49%
267,992 $15.3 Million
Q3 2017

Nov 03, 2017
BUY
$48.06 - $53.64 $13.1 Million - $14.6 Million
272,032
272,032 $14.5 Million

Others Institutions Holding ABT

# of Institutions
3,186
Shares Held
1.3B
Call Options Held
8.74M
Put Options Held
8.08M
View Full List

About ABBOTT LABORATORIES

ABT Quotes by TradingView
  • Ticker ABT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 1,751,219,968
  • Market Cap $206B
  • Description
  • Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for t...
More about ABT
Track This Portfolio

Track John G Ullman & Associates Inc Portfolio

Follow John G Ullman & Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of John G Ullman & Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on John G Ullman & Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email